Lineage Cell Therapeutics (LCTX) EBITDA Margin (2010 - 2026)
Lineage Cell Therapeutics' EBITDA Margin came in at -817.21% for Q2 2026, down 108.03 percentage points from -709.19% a year earlier and down 387.94 percentage points from the prior quarter.
Lineage Cell Therapeutics (LCTX) EBITDA Margin (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Lineage Cell Therapeutics reported EBITDA Margin of -199.58%, up 117.52 percentage points year-over-year; for FY2025, it came in at -246.77%, down 27.07 percentage points from FY2024.
- EBITDA Margin carries a five-year change of +1089.92 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -219.70% in FY2024 (+49.07 pp), -268.76% in FY2023 (-120.54 pp), -148.22% in FY2022 (+965.30 pp) and -1113.52% in FY2021 (+223.17 pp).
- The Q2 2026 figure represents the lowest quarterly EBITDA Margin since Q4 2021.
- Year-over-year, EBITDA Margin increased in four of the last eight quarters, with an average year-over-year change of +29.41 percentage points.
- The fastest year-over-year change in EBITDA Margin over five years came in Q4 2022 (a gain of 2063.63 percentage points), and the weakest in Q4 2021 (a drop of 839.03 percentage points).
- Business Quant data shows LCTX's EBITDA Margin at -429.28% (Q1 2026), -96.28% (Q4 2025) and -98.02% (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Lineage Cell Therapeutics | 245.32 Mn | 43.73 Mn | - | -817.21% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -817.21% |
| Mar 31, 2026 | -429.28% |
| Dec 31, 2025 | -96.28% |
| Sep 30, 2025 | -98.02% |
| Jun 30, 2025 | -709.19% |
| Mar 31, 2025 | -422.17% |
| Dec 31, 2024 | -172.91% |
| Sep 30, 2024 | -97.88% |
| Jun 30, 2024 | -406.61% |
| Mar 31, 2024 | -449.17% |
| Dec 31, 2023 | -296.31% |
| Sep 30, 2023 | -524.00% |
| Jun 30, 2023 | -150.51% |
| Mar 31, 2023 | -271.21% |
| Dec 31, 2022 | -337.65% |
| Sep 30, 2022 | -168.71% |
| Jun 30, 2022 | -89.08% |
| Mar 31, 2022 | -118.73% |
| Dec 31, 2021 | -2,401.28% |
| Sep 30, 2021 | -292.69% |
Lineage Cell Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LCTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "LCTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LCTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();